Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells
- PMID: 2945891
- PMCID: PMC2188458
- DOI: 10.1084/jem.164.5.1547
Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells
Abstract
We have studied the components of a complex of tumor-specific antigens to determine if all of the components of the complex were lost during progression from a rather benign regressor tumor to a highly malignant (HM) cancer. We find that the HM tumor cells have lost antigens recognized by CTL but retained antigens recognized by Th cells. Immunization with variants expressing Th-defined antigens induced tumor-specific immunity to challenge with a parental variant that expressed a CTL-recognized target antigen, but did not induce immunity to challenge with the variant that expressed the Th-defined antigen alone. Together, these findings suggested that Th cells fail to exert direct selective pressure upon the tumor, resulting in retention of "lineage-specific," Th-recognized antigens by highly immunoselected variants. Possible advantage could be taken of this fact for the development of specific immunotherapy.
Similar articles
-
Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.Cancer Res. 1989 Mar 1;49(5):1207-13. Cancer Res. 1989. PMID: 2465081
-
Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.J Immunol. 1986 Apr 1;136(7):2715-9. J Immunol. 1986. PMID: 3005417
-
Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.Tissue Antigens. 1996 May;47(5):399-407. doi: 10.1111/j.1399-0039.1996.tb02575.x. Tissue Antigens. 1996. PMID: 8795140
-
Molecular engineering of the antitumor immune response.Bone Marrow Transplant. 1992;9 Suppl 1:182-6. Bone Marrow Transplant. 1992. PMID: 1387016 Review. No abstract available.
-
Augmenting T helper cell immunity in cancer.Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):365-71. doi: 10.2174/156800805774913006. Curr Drug Targets Immune Endocr Metabol Disord. 2005. PMID: 16375690 Review.
Cited by
-
CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Cell Mol Life Sci. 2018 Feb;75(4):689-713. doi: 10.1007/s00018-017-2686-7. Epub 2017 Oct 14. Cell Mol Life Sci. 2018. PMID: 29032503 Free PMC article. Review.
-
Potential and development of cellular vesicle vaccines in cancer immunotherapy.Discov Oncol. 2025 Jan 15;16(1):48. doi: 10.1007/s12672-025-01781-3. Discov Oncol. 2025. PMID: 39812959 Free PMC article. Review.
-
Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.J Exp Med. 1991 Jan 1;173(1):273-6. doi: 10.1084/jem.173.1.273. J Exp Med. 1991. PMID: 1670640 Free PMC article.
-
Immunogenic capacity of tum--variants isolated from a rat rhabdomyosarcoma.Br J Cancer. 1987 Jul;56(1):7-13. doi: 10.1038/bjc.1987.144. Br J Cancer. 1987. PMID: 2956985 Free PMC article.
-
Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.J Exp Med. 1986 Nov 1;164(5):1516-30. doi: 10.1084/jem.164.5.1516. J Exp Med. 1986. PMID: 3490532 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources